Zastaprazan (trade name Jaqbo) is a pharmaceutical drug for gastrointestinal disorders. It is classified as a potassium-competitive acid blocker.[1][2] In April 2024, it was approved for use in South Korea for the treatment of erosive gastroesophageal reflux disease (GERD).[3] In addition, it is in Phase III clinical trials for gastric ulcer and peptic ulcer.[4]

References

  1. ^ Yang E, Hwang I, Ji SC, Kim J, Lee S (December 2024). "Population pharmacokinetic analysis of zastaprazan (JP-1366), a novel potassium-competitive acid blocker, in patients and healthy volunteers". CPT. 13 (12): 2150–2158. doi:10.1002/psp4.13228. PMC 11646930. PMID 39268835.
  2. ^ Tietto A, Faggin S, Scarpignato C, Savarino EV, Giron MC (September 2024). "Safety of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease". Expert Opinion on Drug Metabolism & Toxicology: 1–16. doi:10.1080/17425255.2024.2397433. PMID 39189409.
  3. ^ Blair HA (July 2024). "Zastaprazan: First Approval". Drugs. 84 (7): 863–866. doi:10.1007/s40265-024-02057-w. PMID 38916840.
  4. ^ "Zastaprazan". AdisInsight. Springer Nature Switzerland AG.


Allikas: https://en.wikipedia.org/wiki/Zastaprazan
No tags for this post.